ZENITH
2025
Sotatercept in High-Risk Pulmonary Arterial Hypertension
In 172 patients with high-risk pulmonary arterial hypertension, sotatercept reduced death, lung transplantation or heart-failure hospitalisation compared with placebo.
Result
Efficacy: Death, lung transplant or PAH hospitalisationHR 0.24
Below 1 favours sotatercept, above 1 favours placebo.
Also reported: (76 % reduction in the primary composite).
- Subtopic
- Activin signalling
- Design
- Double-blind RCT, stopped early
- Relevance
- Important: one of several pillars.
- Source
- Humbert M, et al. N Engl J Med. 2025;392(20):1987-2000.doi 10.1056/NEJMoa2415160
Discussion & critique
Confirmed a hard-outcome benefit in the sickest PAH patients (functional class III–IV). Small and stopped early, which can inflate the effect estimate.